Sure, I'd be happy to explain analyst upgrades in a simple way!

Imagine you have a lemonade stand. Every week, some experts (like analysts) come by and give you advice on how well you're doing because they've seen lots of other lemonade stands too.

1. **Upgrade**: When an analyst upgrades your stock (like from Neutral to Buy), it's like them coming to your lemonade stand and saying:
- "Wow, things are looking even better than we thought last time! You're selling lots more lemonades now."
- They might also raise the price they think you could sell your stand for (the price target).

2. **Downgrade**: When an analyst downgrades your stock (like from Buy to Neutral), it's like them saying:
- "Hmm, we noticed things aren't going as well this time. Maybe you should try making a different flavor of lemonade."

So, when you see upgrades in the news, it means analysts think a company is doing better than they expected, and they're telling investors that they think the stock might be a good buy now. But remember, it's just one person's opinion, and there are always other opinions too! Read from source...

**System Analysts' Stock Rating Changes:**

1. **Eastman Chemical Company (EMN)**
- Old Rating: Equal-Weight
- New Rating: Overweight
- Price Target Increase: $105 to $125

2. **First Interstate BancSystem, Inc. (FIBK)**
- Old Rating: Neutral
- New Rating: Buy
- Price Target Increase: $32 to $42

3. **Hanesbrands Inc. (HBI)**
- Old Rating: Neutral
- New Rating: Buy
- Price Target Increase: $8.45 to $11

4. **Science Applications International Corporation (SAIC)**
- Old Rating: Equal-Weight
- New Rating: Overweight
- Price Target Decrease: $157 to $147

5. **Capri Holdings Limited (CPRI)**
- Old Rating: Neutral
- New Rating: Buy
- New Price Target: $30

**Critique of Analyst Reports:**

Although analyst reports can provide valuable insights, here are a few points that might warrant criticism:

- **Lack of Detail:** Some reports may not provide adequate reasoning behind the change in rating or price target. More detailed explanations could help investors better understand the analysts' perspectives.

- **Subjectivity:** As with any opinion-based analysis, there's an element of subjectivity involved. Different analysts may have varying interpretations of a company's prospects based on their unique research methodologies and viewpoints.

- **Potential Conflicts of Interest:** Analysts may have inherent conflicts of interest if they also work on the issuance or underwriting of securities for the companies they cover, which could potentially bias their ratings.

- **Historical Limitations:** Past performance is not indicative of future results. Stock price movements can be influenced by a multitude of factors beyond a company's fundamentals, so it's essential to remain vigilant and follow up on analysts' recommendations with thorough research of your own.

Based on the article, here is the sentiment for each stock mentioned:

1. **Eastman Chemical Company (EMN)**: Positively bullish
- Rating upgraded from Equal-Weight to Overweight
- Price target increased significantly ($125)

2. **First Interstate BancSystem, Inc. (FIBK)**: Positively bullish
- Rating upgraded from Neutral to Buy
- Price target raised substantially ($42)

3. **Hanesbrands Inc. (HBI)**: Positively bullish
- Rating upgraded from Neutral to Buy
- Price target increased ($11)

4. **Science Applications International Corporation (SAIC)**: Slightly bearish (though the overall recommendation was upgraded)
- Rating upgraded from Equal-Weight to Overweight
- Price target reduced slightly ($147, but still higher than current stock price)

5. **Capri Holdings Limited (CPRI)**: Positively bullish
- Rating upgraded from Neutral to Buy
- New price target set at $30

Based on the provided upgrades, here are comprehensive investment recommendations along with potential risks for each stock:

1. **Eastman Chemical Company (EMN)**
- *Recommendation*: Upgrade to 'Overweight' from 'Equal-Weight'
- *Price Target*: $125 (previous: $110)
- *Upside*: Around 17.9% based on Monday's closing price ($105.84)
- *Risks*:
- Volatility in chemical prices and demand.
- Dependency on key customers for a significant portion of sales.
- Geopolitical risks, especially in emerging markets where the company has operations.

2. **First Interstate BancSystem, Inc. (FIBK)**
- *Recommendation*: Upgrade to 'Buy' from 'Neutral'
- *Price Target*: $42 (previous: $32)
- *Upside*: Around 18.2% based on Monday's closing price ($35.47)
- *Risks*:
- Interest rate risk, as fluctuating interest rates can impact net interest margins.
- Changes in regulatory environment for banking institutions.
- Economic downturns that could lead to increased loan defaults or decreased banking services demand.

3. **Hanesbrands Inc. (HBI)**
- *Recommendation*: Upgrade to 'Buy' from 'Neutral'
- *Price Target*: $11 (previous: $9)
- *Upside*: Around 29.8% based on Monday's closing price ($8.45)
- *Risks*:
- Apparel industry trends and consumer demand for affordable basics.
- Competition from large retailers with their own private-label brands.
- Raw material costs and foreign exchange rate fluctuations.

4. **Science Applications International Corporation (SAIC)**
- *Recommendation*: Upgrade to 'Overweight' from 'Equal-Weight'
- *Price Target*: $147 (previous: $157)
- *Downside*: Around 3.6% based on Monday's closing price ($122.22)
- *Risks*:
- Dependence on government contracts, which can be subject to budget cuts or delays.
- Competition in the government services and IT industry.
- Risks associated with acquisitions and integrations.

5. **Capri Holdings Limited (CPRI)**
- *Recommendation*: Upgrade to 'Buy' from 'Neutral'
- *Price Target*: $30
- *Upside*: Around 43.8% based on Monday's closing price ($21.54)
- *Risks*:
- Luxury goods market volatility and changes in consumer spending.
- Dependency on key designer brands (Jimmy Choo, Versace, Michael Kors).
- Fluctuations in foreign exchange rates due to international operations.

Before making any investment decisions, consider your personal risk tolerance, financial situation, and consult with a financial advisor. These recommendations are based solely on the analysts' sentiments and do not guarantee future performance.